What is INVA stock price today?

INVA (Innoviva Inc) stock is trading at $23.60 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is INVA stock going up or down today?

INVA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy INVA stock now?

The decision to buy INVA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is INVA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for INVA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is INVA stock overvalued or undervalued?

INVA currently trades at a P/E ratio of 7.34, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if INVA is fairly priced.

What is INVA's P/E ratio?

INVA has a price-to-earnings (P/E) ratio of 7.34, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is INVA's market cap?

INVA (Innoviva Inc) has a market capitalization of $1.79 billion, making it a small-cap stock.

What is INVA's price to book ratio?

INVA trades at a price-to-book (P/B) ratio of 1.53, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does INVA pay dividends?

INVA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is INVA's dividend yield?

INVA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is INVA stock a good long-term investment?

INVA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is INVA's revenue growth rate?

INVA has shown revenue growth of 0.2% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, INVA is profitable with a profit margin of 0.7%. This indicates the company generates 0.7 cents of profit for every dollar of revenue.

What are the risks of investing in INVA?

Key risks for INVA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does INVA compare to its competitors?

Compare INVA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize INVA's performance and positioning.

What is INVA's stock price target for 2026?

Our AI model provides price targets for INVA based on fundamental analysis: Bull case $30.68 (+30%), Base case $27.14 (+15%), Bear case $21.24 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about INVA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for INVA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is INVA's next earnings report?

INVA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

INVA - Innoviva Inc

NYSE * Health Care * Biotechnology

$23.60

$-0.32 (-1.34%)

About Innoviva Inc

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Key Statistics

Market Cap

$1.79B

P/E Ratio

7.34

P/B Ratio

1.53

EPS

$3.26

Revenue Growth

+0.2%

Profit Margin

0.7%

Employees

159

How INVA Compares to Peers

INVA has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

INVA has the highest profit margins in Biotechnology

INVA has the fastest revenue growth among competitors

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
INVA(This stock)	$1.79B	7.3	0%	0.7%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Innoviva Inc Company Information

Headquarters: California; U.S.A
Website: www.inva.com
Sector: Health Care
Industry: Biotechnology

INVA - Innoviva Inc

About Innoviva Inc

INVA Key Statistics

How INVA Compares to Peers

Innoviva Inc Company Information

INVA Lician Score

INVA Financial Snowflake

Upcoming Events for INVA